

## Bibliography

- Alidoosti M, Salarifar M, Zeinali AM, Kassaian SE, Dehkordi MR. Comparison of outcomes of percutaneous coronary intervention on proximal versus non-proximal left anterior descending coronary artery, proximal left circumflex, and proximal right coronary artery: a cross-sectional study. *BMC Cardiovasc Disord* 2007;7:7.
- Andersen HR, Nielsen TT, Rasmussen K, *et al.* A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. *N Engl J Med* 2003;349:733-42.
- Anderson JL, Becker LC, Sorensen SG, *et al.* Anistreplase versus alteplase in acute myocardial infarction: comparative effects on left ventricular function, morbidity and 1-day coronary artery patency. The TEAM-3 Investigators. *J Am Coll Cardiol* 1992;20:753-66.
- Andrews J, Straznicky IT, French JK, *et al.* ST-Segment recovery adds to the assessment of TIMI 2 and 3 flow in predicting infarct wall motion after thrombolytic therapy. *Circulation* 2000;101:2138-43.
- Antman EM, Anbe DT, Armstrong PW, *et al.* ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). *Circulation* 2004;110:588-636.
- Antoniucci D, Rodriguez A, Hempel A, *et al.* A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. *J Am Coll Cardiol* 2003;42:1879-85.
- Apstein CS. The benefits of glucose-insulin-potassium for acute myocardial infarction (and some concerns). *J Am Coll Cardiol* 2003;42:792-5.
- B Kantor CJM, A.R. Camrud, L.J. Camrud, J.L. Allen, D.R. Holmes, R.S. Schwartz. Coronary Reperfusion with Aqueous Oxygen Improves Left Ventricular Ejection Fraction and May Reduce Mortality in an Ischemic Porcine Model. *Am J Cardiol* 1998;84:86S (TCT-231).
- Baks T, van Geuns RJ, Biagini E, *et al.* Effects of primary angioplasty for acute myocardial infarction on early and late infarct size and left ventricular wall characteristics. *J Am Coll Cardiol* 2006;47:40-4.
- Bartorelli AL. Hyperoxemic perfusion for treatment of reperfusion microvascular ischemia in patients with myocardial infarction. *Am J Cardiovasc Drugs* 2003;3:253-63.

Bolognese L, Carrabba N, Parodi G, *et al.* Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. *Circulation* 2004;109:1121-6.

Bonnefoy E, Lapostolle F, Leizorovicz A, *et al.* Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. *Lancet* 2002;360:825-9.

Brener SJ, Barr LA, Burchenal JE, *et al.* Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. *Circulation* 1998;98:734-41.

Brereton GJ *et al.* Nucleation in Small Capillary Tubes. *Chemical Phys* 1998;230:253 – 265.

Bridenbaker ML. AIMI: AngioJet Rheolytic Thrombectomy in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction. In: Transcatheter Cardiovascular Therapeutics Conference. Washington, DC: Cardiovascular Research Foundation; 2004:1-4.

Burns RJ, Gibbons RJ, Yi Q, *et al.* The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. *J Am Coll Cardiol* 2002;39:30-6.

Califf RM, Harrelson-Woodlief L, Topol EJ. Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. *Circulation* 1990;82:1847-53.

Cameron AJV *et al.* Haemodynamic and Metabolic Effects of Hyperbaric Oxygen in Myocardial Infarction. *Lancet* 1966;i: 833 – 837.

Chaitman BR, Lim MJ. No reflow and the quest to achieve optimal perfusion during the acute phase of myocardial infarction. *J Am Coll Cardiol* 2004;44:313-5.

Chareonthaitawee P, Gibbons RJ, Roberts RS, Christian TF, Burns R, Yusuf S. The impact of time to thrombolytic treatment on outcome in patients with acute myocardial infarction. For the CORE investigators (Collaborative Organisation for RheothRx Evaluation). *Heart* 2000;84:142-8.

Christian TF, Behrenbeck T, Pellikka PA, Huber KC, Chesebro JH, Gibbons RJ. Mismatch of left ventricular function and infarct size demonstrated by technetium-99m isonitrite imaging after reperfusion therapy for acute myocardial infarction: identification of myocardial stunning and hyperkinesia. *J Am Coll Cardiol* 1990;16:1632-8.

Cleland JG, McGowan J. Heart failure due to ischaemic heart disease: epidemiology, pathophysiology and progression. *J Cardiovasc Pharmacol* 1999;33 Suppl 3:S17-29.

Cowie MR, Wood DA, Coats AJ, *et al.* Survival of patients with a new diagnosis of heart failure: a population based study. *Heart* 2000;83:505-10.

Cowie MRL, Larry; Tabberer, Maggie. Heart Failure After Myocardial Infarction: A Neglected Problem? *British Journal of Cardiology* 2005;12:205-8.

Cox DA, Stone GW, Grines CL, *et al.* Outcomes of optimal or "stent-like" balloon angioplasty in acutemyocardial infarction: the CADILLAC trial. *J Am Coll Cardiol* 2003;42:971-7.

Creech JL *et al.* Injection of Highly Supersaturated Oxygen Solutions without Nucleation. *J Biomech Eng* 2002;124:676 – 683.

De Luca G, Ernst N, Zijlstra F, *et al.* Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty. *J Am Coll Cardiol* 2004;43:1363-7.

De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. *Circulation* 2004;109:1223-5.

De Luca G, Suryapranata H, Zijlstra F, *et al.* Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. *J Am Coll Cardiol* 2003;42:991-7.

Deaths--Leading Causes. National Center for Health Statistics, 2007. (Accessed at [www.cdc.gov/nchs/fastats/lcod.htm](http://www.cdc.gov/nchs/fastats/lcod.htm).)

Dixon SR. Early recovery of infarct zone function with hyperoxemic reperfusion after primary percutaneous transluminal coronary angioplasty. *American Journal of Cardiology* 2000;86 (Suppl. 8A) 8i.

Dixon SR. Global and regional left ventricular function after intracoronary hyperoxemic perfusion with the Aqueous Oxygen system in acute myocardial infarction: TherOx study. *Circulation* 2000;102 (Suppl.):II-386.

Dixon SR, Bartorelli AL, Marcovitz PA, *et al.* Initial experience with hyperoxemic reperfusion after primary angioplasty for acute myocardial infarction: results of a pilot study utilizing intracoronary aqueous oxygen therapy. *J Am Coll Cardiol* 2002;39:387-92.

Dixon SR, Whitbourn RJ, Dae MW, *et al.* Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction. *J Am Coll Cardiol* 2002;40:1928-34.

Drug-Eluting Stent Overview. 2006. (Accessed October 30, 2006, 2006, at <http://www.angioplasty.org>.)

Duan N. Smearing estimate: a nonparametric retransformation method. *J Am Stat Ass* 1983;78:605-10.

Elsman P, van t Hof AW, Hoorntje JC, *et al.* Effect of coronary occlusion site on angiographic and clinical outcome in acute myocardial infarction patients treated with early coronary intervention. *Am J Cardiol* 2006;97:1137-41.

Faxon DP. Coronary interventions and their impact on post myocardial infarction survival. *Clin Cardiol* 2005;28:138-44.

Fishbein MC, Meerbaum S, Rit J, *et al.* Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. *Am Heart J* 1981;101:593-600.

Gibbons RJ, Christian TF, Hopfenspirger M, Hodge DO, Bailey KR. Myocardium at risk and infarct size after thrombolytic therapy for acute myocardial infarction: implications for the design of randomized trials of acute intervention. *J Am Coll Cardiol* 1994;24:616-23.

Gibbons RJ, Miller TD, Christian TF. Infarct size measured by single photon emission computed tomographic imaging with (99m)Tc-sestamibi: A measure of the efficacy of therapy in acute myocardial infarction. *Circulation* 2000;101:101-8.

Gibbons RJ, Valeti US, Araoz PA, Jaffe AS. The quantification of infarct size. *J Am Coll Cardiol* 2004;44:1533-42.

Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. *Circulation* 2002;105:1909-13.

Gibson CM, de Lemos JA, Antman EM. Time is muscle in primary PCI: the strength of the evidence grows. *Eur Heart J* 2004;25:1001-2.

Gibson CMM, Sabina A.; McCabe, Carolyn H.; Giugliano, Robert P.; Cannon, Christopher P.; Antman, Elliott; Braunwald, Eugene. Time is Muscle: Delays in Time from Symptom Onset to Fibrinolytic Administration in ST Elevation MI are Associated with Proper Myocardial Perfusion. Boston, MA: TIMI Study Group; 2003.

Gibson M. Time is Myocardium and Time is Outcomes. *Circulation* 2001;104:2632-4.

Grines CL, Cox DA, Stone GW, *et al.* Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. *N Engl J Med* 1999;341:1949-56.

Group ISAMS. A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.) Mortality, morbidity, and infarct size at 21 days. The I.S.A.M. Study Group. *The New England Journal of Medicine* 1986;314:1465-71.

Heart Attack and Angina Statistics. 2007. (Accessed May 7, 2007, at <http://www.americanheart.org/presenter.jhtml?identifier=4591>.)

Herrmann HC, Moliterno DJ, Ohman EM, *et al.* Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. *J Am Coll Cardiol* 2000;36:1489-96.

Hillis GS, Mulvagh SL, Pellikka PA, *et al.* Comparison of intravenous myocardial contrast echocardiography and low-dose dobutamine echocardiography for predicting left ventricular functional recovery following acute myocardial infarction. *Am J Cardiol* 2003;92:504-8.

In: Cardiovascular and renal drugs advisory committee in collaboration with the blood products advisory committee, subcommittee; 1992.

Jain KK. *Textbook of Hyperbaric Medicine*. Hogrefe and Huber Publishers, 1999.

J. R. Cameron JGS, Roderick M. Grant. In: *Physics of the Body*. 2nd ed. Madison, WI: Medical Physics Publishing Corporation; 1999:394.

Kastrati A, Mehilli J, Dirschinger J, *et al.* Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. *Lancet* 2002;359:920-5.

Kastrati A, Mehilli J, Nekolla S, *et al.* A randomized trial comparing myocardial salvage achieved by coronary stenting versus balloon angioplasty in patients with acute myocardial infarction considered ineligible for reperfusion therapy. *J Am Coll Cardiol* 2004;43:734-41.

Kaul S, Ito H. Microvasculature in acute myocardial ischemia: part I: evolving concepts in pathophysiology, diagnosis, and treatment. *Circulation* 2004;109:146-9.

Kaul S, Ito H. Microvasculature in acute myocardial ischemia: part II: evolving concepts in pathophysiology, diagnosis, and treatment. *Circulation* 2004;109:310-5.

Keeley EC, Grines CL. Primary coronary intervention for acute myocardial infarction. *JAMA* 2004;291:736-9.

Kennedy JW, Martin GV, Davis KB, *et al.* The Western Washington Intravenous Streptokinase in Acute Myocardial Infarction Randomized Trial. *Circulation* 1988;77:345-52.

Kloner RA, Forman MB, Gibbons RJ, Ross AM, Alexander RW, Stone GW. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. *Eur Heart J* 2006;27:2400-5.

Klootwijk P, Langer A, Meij S, *et al.* Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-I trial. *Eur Heart J* 1996;17:689-98.

Krucoff MW, Croll MA, Pope JE, *et al.* Continuous 12-lead ST-segment recovery analysis in the TAMI 7 study. Performance of a noninvasive method for real-time detection of failed myocardial reperfusion. *Circulation* 1993;88:437-46.

Krucoff MW, Croll MA, Pope JE, *et al.* Continuously updated 12-lead ST-segment recovery analysis for myocardial infarct artery patency assessment and its correlation with multiple simultaneous early angiographic observations. *Am J Cardiol* 1993;71:145-51.

Krucoff MW, Green CE, Satler LF, *et al.* Noninvasive detection of coronary artery patency using continuous ST-segment monitoring. *Am J Cardiol* 1986;57:916-22.

Laarman GJ, Suttorp MJ, Dirksen MT, *et al.* Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. *N Engl J Med* 2006;355:1105-13.

Langer A, Krucoff MW, Klootwijk P, *et al.* Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: the GUSTO-I ST Segment Monitoring Substudy. *J Am Coll Cardiol* 1998;31:783-9.

Leborgne L, Cheneau E, Wolfram R, *et al.* The proximal location of stenosis in the left anterior descending coronary artery is not a predictive factor of worse outcome in the era of the stent. *Cardiovasc Radiat Med*;3:127-32.

Lewis EF, Moye LA, Rouleau JL, *et al.* Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. *J Am Coll Cardiol* 2003;42:1446-53.

Limbruno U, De Caterina R. EMERALD, AIMI, and PROMISE: is there still a potential for embolic protection in primary PCI? *Eur Heart J* 2006;27:1139-45.

- Lund GK, Stork A, Saeed M, *et al.* Acute myocardial infarction: evaluation with first-pass enhancement and delayed enhancement MR imaging compared with 201Tl SPECT imaging. *Radiology* 2004;232:49-57.
- Luo AK, Wu KC. Imaging microvascular obstruction and its clinical significance following acute myocardial infarction. *Heart Fail Rev* 2006;11:305-12.
- Magnani B. Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction. *J Am Coll Cardiol* 1989;13:19-26.
- Mark H. Beers RB, ed. *The Merck Manual of Diagnosis and Therapy*. 17th ed: Merck and Company; 1999.
- Mehta RH, Sadiq I, Goldberg RJ, *et al.* Effectiveness of primary percutaneous coronary intervention compared with that of thrombolytic therapy in elderly patients with acute myocardial infarction. *Am Heart J* 2004;147:253-9.
- Miller KE. Adenosine for Reducing Infarction Size in Acute MI. *American Family Physician* 2000;1-2.
- Miller TD, Christian TF, Hopfenspirger MR, Hodge DO, Gersh BJ, Gibbons RJ. Infarct size after acute myocardial infarction measured by quantitative tomographic 99mTc sestamibi imaging predicts subsequent mortality. *Circulation* 1995;92:334-41.
- Miller TD, Hodge DO, Sutton JM, *et al.* Usefulness of technetium-99m sestamibi infarct size in predicting posthospital mortality following acute myocardial infarction. *Am J Cardiol* 1998;81:1491-3.
- Montalescot G, Barragan P, Wittenberg O, *et al.* Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. *N Engl J Med* 2001;344:1895-903.
- Moons KG, Klotwijk P, Meij SH, *et al.* Continuous ST-segment monitoring associated with infarct size and left ventricular function in the GUSTO-I trial. *Am Heart J* 1999;138:525-32.
- Myocardial Infarction. 2007. (Accessed January 8, 2008, at [http://en.wikipedia.org/wiki/Myocardial\\_infarction](http://en.wikipedia.org/wiki/Myocardial_infarction).)
- Neuhaus KL, Tebbe U, Gottwik M, *et al.* Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS). *J Am Coll Cardiol* 1988;12:581-7.

Newby LK, Rutsch WR, Califf RM, *et al.* Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. J Am Coll Cardiol 1996;27:1646-55.

Newell MC, Henry CR, Sigakis CJ, *et al.* Comparison of safety and efficacy of sirolimus-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2006;97:1299-302.

Otieno HA. Acute Myocardial Infarction in 2004: Reperfusion, Support, and Pharmacology. Cardiac Interventions 2004;16-21.

R.J.A. Little DBR. Statistical Analysis with Missing Data. 2nd ed. New York: John Wiley & Sons, Inc.; 2002.

Risk Factors and Coronary Heart Disease. 2007. (Accessed June 19, 2007, at [http://www.americanheart.org/print\\_presenter.jhtml;jsessionid=DTRYZHNDVE4UECQFCXPSDQ?identifier=4726](http://www.americanheart.org/print_presenter.jhtml;jsessionid=DTRYZHNDVE4UECQFCXPSDQ?identifier=4726).)

Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005;45:1775-80.

Salloum J, Tharpe C, Vaughan D, Zhao DX. Release and elimination of soluble vasoactive factors during percutaneous coronary intervention of saphenous vein grafts: analysis using the PercuSurge GuardWire distal protection device. J Invasive Cardiol 2005;17:575-9.

Schiller NB, Shah PM, Crawford M, *et al.* Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-67.

Schomig AK, Adnan; Dirschinger, Josef; Mehilli, Julinda; Schricke, Ullrich; Pache, Jurgen; Martinoff, Stefan; Neumann, Franz-Josef; Schwaiger, Markus. Coronary Stenting Plus Platelet Glycoprotein IIb/IIIa Blockade Compared With Tissue Plasminogen Activator in Acute Myocardial Infarction. The New England Journal of Medicine 2000;343:385-91.

Shah A, Wagner GS, Granger CB, *et al.* Prognostic implications of TIMI flow grade in the infarct related artery compared with continuous 12-lead ST-segment resolution analysis. Reexamining the "gold standard" for myocardial reperfusion assessment. J Am Coll Cardiol 2000;35:666-72.



Shandling AH *et al.* Hyperbaric Oxygen and Thrombolysis in Myocardial Infarction: the "Hot MI" Pilot Study. *Am Heart J* 1997;134:544 – 550.

Sharifi M *et al.* Reduction in Clinical Restenosis by Hyperbaric Oxygen Therapy: A Year Later. Presented at the Transcatheter Cardiovascular Therapeutics Conference, September 15 – 19, 2003.

Spaulding C, Henry P, Teiger E, *et al.* Sirolimus-eluting versus uncoated stents in acute myocardial infarction. *N Engl J Med* 2006;355:1093-104.

Spears J. Reperfusion Microvascular Ischemia: Attenuation with Aqueous Oxygen. *Circulation* 2000;102:646(3132).

Spears JR, Henney C, Prcevski P, *et al.* Aqueous oxygen hyperbaric reperfusion in a porcine model of myocardial infarction. *J Invasive Cardiol* 2002;14:160-6.

Spears JR, Prcevski P, Xu R, *et al.* Aqueous oxygen attenuation of reperfusion microvascular ischemia in a canine model of myocardial infarction. *ASAIO J* 2003;49:716-20.

Spears JR *et al.* Hyperoxemic Reperfusion with Aqueous Oxygen Improves Left Ventricular Function and Microvascular Flow in the Postischemic Canine Myocardium. *J Am Coll Cardiol* 1998;31:Abstr Suppl A: 449A (1185 – 127).

Spiegelhalter DJ, Best DJ, Carlin BP, van der Linde A. Bayesian measures of model complexity and fit (with discussion). *J Roy Stat Soc, Series B* 2002;64:583-639.

Stone GW. Shifting Paradigms in Pharmacologic and Interventional Therapies for ACS and AMI. In: Transcatheter Cardiovascular Therapeutics Conference. Washington, DC: Cardiovascular Research Foundation; 2006.

Stone GW, Cox D, Garcia E, *et al.* Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. *Circulation* 2001;104:636-41.

Stone GW, Grines CL, Cox DA, *et al.* Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. *N Engl J Med* 2002;346:957-66.

Stone GW, Webb J, Cox DA, *et al.* Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. *JAMA* 2005;293:1063-72.

Stone PH, Raabe DS, Jaffe AS, et al. Prognostic significance of location and type of myocardial infarction: independent adverse outcome associated with anterior location. *J Am Coll Cardiol* 1988;11:453-63.

Swilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coronary intervention. *N Engl J Med* 2008;358:557-67.

Swift PC *et al.* (1992). Myocardial Hibernation Identified by Hyperbaric Oxygen Treatment and Echocardiography in Post infarction Patients: Comparison with Exercise Thallium Scintigraphy. *Am Heart J* 124:1151 – 1158.

The World Health Report 2004 -- Changing History; 2004.

Thurston JG *et al.* (1974). A Controlled Investigation into the Effects of Hyperbaric Oxygen on Mortality Following Acute Myocardial Infarction. *Q J Med* 42:751 – 770.

Trabattoni D. Cardiac Enzyme Kinetic, ST-segment Evolutionary Changes and Left Ventricular Function Recovery in Patients with Anterior AMI Treated with Primary PCI Followed by LAD Hyperoxemic Blood Infusion. In: 34th Congresso Nazionale di Cardiologia. Florence, Italy; 2003.

van der Horst IC, Zijlstra F, van 't Hof AW, et al. Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. *J Am Coll Cardiol* 2003;42:784-91.

Van der Werf F A. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, survival in acute myocardial infarction. *British Medical Journal* 1988;297:1374-9.

Veldkamp RF, Green CL, Wilkins ML, et al. Comparison of continuous ST-segment recovery analysis with methods using static electrocardiograms for noninvasive patency assessment during acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 7 Study Group. *Am J Cardiol* 1994;73:1069-74.

Veldkamp RF, Pope JE, Sawchak ST, Wagner GS, Califf RM, Krucoff MW. ST-segment recovery as an endpoint in acute myocardial infarction trials. Past, present, and future. *J Electrocardiol* 1993;26 Suppl:256-61.

White HD, Rivers JT, Maslowski AH, et al. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. *N Engl J Med* 1989;320:817-21.

Widimsky P, Bilkova D, Penicka M, et al. Long-term outcomes of patients with acute myocardial infarction presenting to hospitals without catheterization laboratory and randomized to immediate thrombolysis or interhospital transport for primary percutaneous coronary intervention. Five years' follow-up of the PRAGUE-2 Trial. *Eur Heart J* 2007;28:679-84.

Zahn R, Hamm CW, Schneider S, et al. Predictors of death or myocardial infarction during follow-up after coronary stenting with the sirolimus-eluting stent. Results from the prospective multicenter German Cypher Stent Registry. *Am Heart J* 2006;152:1146-52.

Zijlstra F, Hoorntje JC, de Boer MJ, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. *N Engl J Med* 1999;341:1413-9.